Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Excessive Drug Pricing: What It Is, And What It Isn't

Executive Summary

It's difficult to know exactly how to define "excessive" or "unfair" pricing where pharmaceutical products are concerned, and many factors have to be taken into account. Even the EU Commission and competition authorities may be reluctant to pursue cases of alleged price gouging, lawyer David Hull told Informa's recent EU Pharma Law Forum in Brussels.

Advertisement

Related Content

UK Decision Soon On Pfizer/Flynn’s “Excessive” Phenytoin Price Rises
Handling Drug Price Spikes: A Sad Place To Be

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register